Ocugen CEO Musunuri sells $589,109 in shares, priced $1.06-$1.31

Ocugen CEO Shankar Musunuri recently sold $589,109 worth of company shares, according to a recent SEC filing. This sale occurred on September 9, 2026, when Ocugen's stock was trading near its 52-week low of $1.01, at a price of $1.02. The transactions consisted of the direct sale of 468,727 shares, priced between $1.06 and $1.31 per share.

Additionally, 57,264 shares were sold indirectly through KVM Holdings, LLC at prices ranging from $1.11 to $1.14 per share. Musunuri is a director and officer of KVM Holdings, LLC, which allowed him to own and sell shares in both his direct and indirect capacities. Following the transactions, Musunuri now owns 4,487,197 shares directly and 1,088,035 shares indirectly.

The stock's recent decline, following a 25% drop over the past week, has led some analysts to conclude that the stock may be overvalued at current levels. Ocugen reported its second-quarter 2026 financial results, exceeding analyst expectations with $1.48 million in revenue. However, the company still posted an adjusted loss of $0.07 per share, wider than the anticipated $0.05 loss per share.

Despite the financial challenges, H.C. Wainwright adjusted its price target for Ocugen to $9.50 from $10.00, maintaining a Buy rating on the stock. This adjustment was prompted by a delay in the Phase 2/3 GARDian3 trial for OCU410ST, which assesses the efficacy of Ocugen's potential Stargardt disease treatment.